Click here to post a new related report
Intradigm closes $21.4M for cancer therapeutics
Biotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer. The Palo Alto, Calif.-based company says it distinguishes...
-
- Share:
-
-
-
-
-
-
Reach -
Credibility
-
News Stories
- News Source: Venture Beat | 10 months agoBiotech firm Intradigm has tacked an additional $2.9 million onto its second round of funding, bringing its total to $21.4 million. The new money will be used to advance its RNA interference-based line of therapeutics used to treat cancer. The Palo...
- News Source: Androscoggin News | 10 months agoIntradigm Corp. closed the final tranche, worth $2.9 million, of its second round of venture funding...Philip Haworth will become CEO — he was the company’s vice president of business development. This bit of funding, led by Astellas Venture...
- News Source: Uinta County News | 10 months agoIntradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced that the company has closed the final tranche of its Series B financing. Astellas Venture Management led the $2.9 million tranche,...
Site Links
Site Topics
Contributions
- Report Your News
- Add your voice and contribute via your cellphone - check out how to Report News via Your Cellphone
- Blog Widget
- Widget for Blog Owner
